Julie Schurgers

Advanced Animal Diagnostics, Inc. develops integrated systems and solutions for the detection of animal diseases. The firm engages in the researching, developing and commercializing on-farm diagnostic tests, such as QScout MLD for early detection of subclinical mastitis in dairy cows. It also provides solutions for the diagnosis and treatment of veterinary health problems including mastitis and other animal diseases. The company was founded by Rodolfo Rodriguez and Victor M. Minton in July 2001 and is headquartered in Durham, NC.

Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

DoseVue NV is developing innovative technologies for convenient and accurate in-vivo dosimetry. It offers DoseWire Series 100 & DoseWire Series 200. The company was founded by Emiliano D Agostino in March 2013 and is headquartered in Turnhout, Belgium.

ViroVet NV is a Belgian company that focuses on the discovery, licensing, and development of biopharmaceutical products for livestock. The company is based in Leuven, Belgium. ViroVet was founded by Erwin Blomsma, Stefaan Wera, and Nesya Goris, with Erwin Blomsma serving as the CEO since incorporation.

Innovation Fund is a venture capital firm founded in 2015. The firm headquartered located in Schaerbeek, Belgium.

Theodorus Investment Funds is a venture capital firm founded in 2003. The firm headquartered in Brussels, Belgium.

Roslin Technologies Ltd. engages in the provision of agriculture biotechnology solutions. It offers genome sequencing, genotyping, gene editing, transgenics, phenotyping, and bioinformatics. The company is headquartered in Midlothian, the United Kingdom.

Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020.

AnimAb BV is a Belgian company that focuses on improving animal performance through its antibody-based approach that targets intestinal pathogens. AnimAb is based in Ghent, Belgium. The company helps protect piglets during their most fragile post-weaning stage. AnimAb integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies, and sustainability. The company's technology prevents intestinal bacterial colonization thanks to the direct integration with animal feed. The company's cross-disciplinary science teams developed a new antibody technology designed for oral ingestion based on a scalable, cost-effective microbial production process. The company was founded in 2020 by Eric Cox, Henri de Greve, Ann Depicker, and Nico Callewaert. Alain Wille has been the CEO of the company since 2020.

Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer.

Home EOS NV is a company based in Farciennes, Belgium. Home EOS specializes in providing a serene and healthy living environment with effective and ecological acoustic insulation. The Belgian company was founded in 2014 and Pierre P. de Kettenis de Hollaeken has been the CEO of the company since 2016.

NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke.